The remaining EGFR variants transformed Ba/F3 cells and demonstrated similar doubling time to that of the parental cells provided IL‐3 (Table 1), indicating that these cancer‐derived variants are indeed EGFR activating mutations. The gene discussed is EGFR; the disease is cancer.